Innovative Ultrasound Helmet Facilitates Non-Invasive Deep Brain Stimulation
A novel ultrasound helmet enables non-invasive, targeted stimulation of deep brain structures, promising advances in neuroscience research and treatment of neurological disorders without surgery.
Researchers from University College London and the University of Oxford have developed a groundbreaking ultrasound helmet that enables precise stimulation of deep brain regions without the need for surgical intervention. This innovative device opens new doors for both neurological research and the treatment of disorders such as Parkinson's disease by allowing scientists and clinicians to modulate brain activity with unprecedented accuracy. Traditional transcranial ultrasound stimulation (TUS) techniques have struggled to reach deep brain structures with sufficient precision, often affecting broader areas than intended. The new system overcomes these limitations by employing a helmet equipped with 256 focused ultrasound elements that target specific neural circuits, along with a soft plastic face mask that stabilizes the head for accurate targeting.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Risks of Whooping Cough in Infants Highlight Importance of Vaccination
Pertussis, or whooping cough, is rising and poses a severe risk to young infants. Vaccination during pregnancy is essential for their protection. Learn more about prevention and treatment.
Predicting Severity of Traumatic Injuries in Pedestrian Car Collisions Using Age and Location Data
Recent research reveals that age and location data can help predict the severity of injuries sustained by pedestrians in vehicle accidents, aiding targeted prevention efforts.
Epigenetic Interplay Influences Cell Development and Disease Progression
New research uncovers how two epigenetic markers work together to regulate cell development and their implications in neurodevelopmental and blood cancers, opening new therapeutic possibilities.
FDA Approves Injectable Leqembi for Early Alzheimer's Disease Treatment
The FDA has approved Leqembi Iqlik, a new subcutaneous injectable for early Alzheimer's disease, offering a faster, more convenient treatment option for patients after initial IV therapy.